Saks Jazz's up Tonix board
This article was originally published in Scrip
Former CEO of Jazz Pharmaceuticals Dr Samuel Saks has joined the board of specialty CNS company Tonix Pharmacueticals. Dr Saks co-founded Jazz in 2003, and remained there as CEO and a director until his resignation in 2009.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.